Donas do Mounjaro e do Ozempic aumentam previsão de lucro com boom de canetas emagrecedoras

Novo Nordisk's raised forecast fails to change the debate over its obesity business

Novo Nordisk hiked guidance to flat on Wegovy (5M+ prescriptions) but Eli Lilly's share gains and weak CagriSema results disappointed. Stock down 70% signals pipeline weakness and execution risk as obesity pioneer loses leadership to faster competitors.